Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,777 across all filing types
Latest filing 2018-04-27 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
2017年度审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a 2017 annual report on the Audit Committee's performance by the board of directors of the company. It details the Audit Committee's activities, meetings, evaluations of external auditors, internal audit guidance, review of financial reports, internal control assessments, and overall evaluation for the year 2017. It is a standalone report focused on audit committee duties and audit-related oversight, not the full annual report or financial statements themselves. The document length is 3116 characters, which is relatively short but contains substantive content about audit committee work rather than just an announcement or certification. Therefore, it fits best as an Audit Report / Information (AR) filing, which covers standalone audit reports and related audit committee information, excluding full annual reports. FY 2017
2018-04-27 Chinese
第九届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the 9th Board of Directors of 金宇生物技术股份有限公司 (Jinyu Biotechnology Co., Ltd.) held on April 26, 2018. It includes approvals of various reports such as the 2017 Annual Report, 2018 Q1 Report, financial reports, profit distribution plan, internal control evaluation, audit committee report, and other corporate governance matters. It also mentions the scheduling of the 2017 Annual General Meeting (AGM) for May 18, 2018. The document is a formal announcement of board meeting decisions rather than the full reports themselves. It contains voting results and decisions on multiple agenda items but does not include the full text of the reports or financial statements. Therefore, it is best classified as a Board/Management Information filing (MANG), which covers announcements of board decisions and management changes or approvals.
2018-04-27 Chinese
关于增加闲置自有资金进行现金管理投资额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company regarding an increase in the investment limit for cash management using idle funds. It details the board resolutions, investment products, risk control measures, and opinions of independent directors and the supervisory board. The document is a formal public announcement about a financing or capital management activity, specifically about increasing the cash management investment quota. It does not contain financial statements, audit information, or detailed financial results. It is not a report but an announcement of a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 2644 characters, which is consistent with an announcement rather than a full report.
2018-04-27 Chinese
关于2017年度限制性股票股权激励计划预留限制性股票数量调整及授予相关事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the adjustment and granting of reserved restricted stock under a 2017 equity incentive plan. It details the board and supervisory meetings, approval processes, legal and financial advisor opinions, and specifics about the stock grant such as quantity, price, recipients, and impact on financials. The document is a formal announcement of a share-based compensation plan adjustment and grant, not a full financial report or audit. It does not contain comprehensive financial statements or quarterly/annual financial results. It is not a proxy solicitation or voting result announcement. The content fits best under a Capital/Financing Update (CAP) as it relates to equity incentive plan share grants and adjustments, which affect the company's capital structure and financing arrangements.
2018-04-27 Chinese
2017年度限制性股票股权激励计划预留限制性股票激励对象名单
Share Issue/Capital Change Classification · 95% confidence The document is a list of reserved restricted stock incentive recipients for a biotechnology company for the year 2017. It details the allocation of restricted stock to middle management and core technical personnel, including names and positions. There is no indication of financial statements, audit information, meeting materials, voting results, or other report types. The content focuses on stock incentive plan details, which is related to share issuance or capital changes. Given the nature of the document as an announcement of stock incentive allocations, it fits best under the category of Share Issue/Capital Change (SHA). The document length is short and it is not a report publication announcement or a certification, so SHA is appropriate.
2018-04-27 Chinese
关于召开2017年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2017 Annual General Meeting (AGM) of 金宇生物技术股份有限公司, including details on the meeting date, voting procedures, agenda items, and proxy authorization. It does not contain the actual annual report or financial statements but rather the announcement and logistical information for the AGM. The document length is 3756 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2018-04-27 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.